Search

Your search keyword '"Papaccio, Federica"' showing total 11 results
Start Over Author "Papaccio, Federica" Publisher elsevier bv
11 results on '"Papaccio, Federica"'

2. Detection of postoperative plasma circulating tumour DNA and lack of CDX2 expression as markers of recurrence in patients with localised colon cancer

Author

Tarazona, Noelia, primary, Gimeno-Valiente, Francisco, additional, Gambardella, Valentina, additional, Huerta, Marisol, additional, Roselló, Susana, additional, Zuniga, Sheila, additional, Calon, Alexandre, additional, Carbonell-Asins, Juan Antonio, additional, Fontana, Elisa, additional, Martinez-Ciarpaglini, Carolina, additional, Eason, Katherine, additional, Rentero-Garrido, Pilar, additional, Fleitas, Tania, additional, Papaccio, Federica, additional, Moro-Valdezate, David, additional, Nyamundanda, Gift, additional, Castillo, Josefa, additional, Espí, Alejandro, additional, Sadanandam, Anguraj, additional, Roda, Desamparados, additional, and Cervantes, Andrés, additional

Published
2020
Full Text
View/download PDF

3. Ex vivo lung cancer spheroids resemble treatment response of a patient with NSCLC to chemotherapy and immunotherapy: case report and translational study

Author

Di Liello, Raimondo, primary, Ciaramella, Vincenza, additional, Barra, Giusi, additional, Venditti, Massimo, additional, Della Corte, Carminia Maria, additional, Papaccio, Federica, additional, Sparano, Francesca, additional, Viscardi, Giuseppe, additional, Iacovino, Maria Lucia, additional, Minucci, Sergio, additional, Fasano, Morena, additional, Ciardiello, Fortunato, additional, and Morgillo, Floriana, additional

Published
2019
Full Text
View/download PDF

4. In the literature: August 2018

Author

Gambardella, Valentina, primary, Bruixola, Gema, additional, Papaccio, Federica, additional, Cejalvo, Juan-Miguel, additional, and Cervantes, Andrés, additional

Published
2019
Full Text
View/download PDF

6. Prognostic Nutritional Index as an independent prognostic factor in locoregionally advanced squamous cell head and neck cancer

Author

Bruixola, Gema, primary, Caballero, Javier, additional, Papaccio, Federica, additional, Petrillo, Angelica, additional, Iranzo, Aina, additional, Civera, Miguel, additional, Moriana, Miriam, additional, Bosch, Neus, additional, Maroñas, Maria, additional, González, Ines, additional, Pastor, Miguel, additional, and Cervantes, Andrés, additional

Published
2018
Full Text
View/download PDF

7. Results of the safety run-in part of the METAL (METformin in Advanced Lung cancer) study: a multicentre, open-label phase I–II study of metformin with erlotinib in second-line therapy of patients with stage IV non-small-cell lung cancer

Author

Morgillo, Floriana, primary, Fasano, Morena, additional, Della Corte, Carminia Maria, additional, Sasso, Ferdinando Carlo, additional, Papaccio, Federica, additional, Viscardi, Giuseppe, additional, Esposito, Giovanna, additional, Di Liello, Raimondo, additional, Normanno, Nicola, additional, Capuano, Annalisa, additional, Berrino, Liberato, additional, Vicidomini, Giovanni, additional, Fiorelli, Alfonso, additional, Santini, Mario, additional, and Ciardiello, Fortunato, additional

Published
2017
Full Text
View/download PDF

9. Regulatory T cells, inflammation, and endoplasmic reticulum stress in women with defective endometrial receptivity

Author

Galgani, Mario, primary, Insabato, Luigi, additional, Calì, Gaetano, additional, Della Gatta, Anna Nunzia, additional, Mirra, Paola, additional, Papaccio, Federica, additional, Santopaolo, Marianna, additional, Alviggi, Carlo, additional, Mollo, Antonio, additional, Strina, Ida, additional, Matarese, Giuseppe, additional, Beguinot, Francesco, additional, De Placido, Giuseppe, additional, and Ulianich, Luca, additional

Published
2015
Full Text
View/download PDF

10. A Multicenter, Open-Label Phase II Study of Metformin With Erlotinib in Second-Line Therapy of Stage IV Non–Small-Cell Lung Cancer Patients: Treatment Rationale and Protocol Dynamics of the METAL Trial

Author

Fasano, Morena, primary, Della Corte, Carminia Maria, additional, Capuano, Annalisa, additional, Sasso, Ferdinando Carlo, additional, Papaccio, Federica, additional, Berrino, Liberato, additional, Ciardiello, Fortunato, additional, and Morgillo, Floriana, additional

Published
2015
Full Text
View/download PDF

11. Results of the safety run-in part of the METAL (METformin in Advanced Lung cancer) study: a multicentre, open-label phase I–II study of metformin with erlotinib in second-line therapy of patients with stage IV non-small-cell lung cancer

Author

Ferdinando Carlo Sasso, Liberato Berrino, Carminia Maria Della Corte, Giuseppe Viscardi, Giovanna Esposito, Alfonso Fiorelli, Mario Santini, Giovanni Vicidomini, Annalisa Capuano, Federica Papaccio, Morena Fasano, Nicola Normanno, Raimondo Di Liello, Fortunato Ciardiello, Floriana Morgillo, Morgillo, Floriana, Fasano, Morena, Della Corte, Carminia Maria, Sasso, Ferdinando Carlo, Papaccio, Federica, Viscardi, Giuseppe, Esposito, Giovanna, Di Liello, Raimondo, Normanno, Nicola, Capuano, Annalisa, Berrino, Liberato, Vicidomini, Giovanni, Fiorelli, Alfonso, Santini, Mario, and Ciardiello, Fortunato

Subjects
0301 basic medicine, Oncology, erlotinib, Cancer Research, medicine.medical_specialty, LKB1, medicine.drug_class, NSCLC, Erlotinib, Metformin, Population, Pharmacology, Tyrosine-kinase inhibitor, 03 medical and health sciences, 0302 clinical medicine, Gefitinib, Internal medicine, medicine, Epidermal growth factor receptor, Adverse effect, education, Lung cancer, Original Research, education.field_of_study, biology, business.industry, medicine.disease, respiratory tract diseases, 030104 developmental biology, 030220 oncology & carcinogenesis, biology.protein, metformin, business, medicine.drug
Abstract

Our previous works demonstrated the ability of metformin to revert resistance to gefitinib, a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in non-small-cell lung cancer (NSCLC) EGFR/LKB1 wild-type (WT) cell lines. However, the optimal dose of metformin to be used in non-diabetic patients still remains to be defined. The phase I-II trial METformin in Advanced Lung cancer (METAL) was designed to identify the maximum tolerated dose and to evaluate safety and activity of metformin combined with erlotinib in second-line treatment of patients with stage IV NSCLC, whose tumours harbour the WT EGFR gene. Purpose Our previous works demonstrated the ability of metformin to revert resistance to gefitinib, a selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in non-small-cell lung cancer (NSCLC) EGFR/LKB1 wild-type (WT) cell lines. However, the optimal dose of metformin to be used in non-diabetic patients still remains to be defined. The phase I-II trial METformin in Advanced Lung cancer (METAL) was designed to identify the maximum tolerated dose and to evaluate safety and activity of metformin combined with erlotinib in second-line treatment of patients with stage IV NSCLC, whose tumours harbour the WT EGFR gene.Patients and methods We report results from the safety run-in part designed to detect acute toxicities, to study pharmacokinetics and to identify the recommended phase II dose (RPD) to be used for the following phase of the study. In the run-in phase, metformin treatment was administered according to a dose escalation scheme and, subsequently, combined with erlotinib.Results Twelve patients were enrolled. Common adverse events were diarrhoea, decreased appetite, abdominal pain, vomiting and skin toxicity, mostly reversible with symptomatic medical treatment. Dose-limiting toxicities were vomiting and diarrhoea registered in the initial cohort receiving metformin 2000 mg plus erlotinib at 150 mg die, which was declared the maximum administered dose. Only one of nine patients treated at the next lower dose of 1500 mg of metformin plus erlotinib at 150 mg experienced G3 gastrointestinal toxicity. Metformin plasma-concentration profile confirmed the trend already observed in nondiabetic population. Glycemic profiles showed stability of the blood glucose level within the physiological range for non-diabetic subjects. At a follow-up of 30 weeks, six (50%) patients experienced a disease control (5 SD and 1 partial response).Conclusions The RP2D of metformin dose was defined at 1500 mg/day to be combined with erlotinib 150 mg.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results